Neuroendocrine Risk for PTSD in Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-11

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase):

1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD
2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD
3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported)

Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perimenopausal Effects of Estradiol on Reward Responsiveness

NCT02255175

Perimenopausal Depression

COMPLETED PHASE4

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320

Perinatal Depression Post Partum Depression Depression, Postpartum +1 more

COMPLETED PHASE2

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322

Healthy Volunteers

COMPLETED PHASE1/PHASE2

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277

Depression Psychosis Anhedonia

RECRUITING PHASE4

Combined Hormone Replacement in Menstrually-Related Mood Disorders

NCT00005011

Premenstrual Syndrome Depression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The majority of Americans will experience a traumatic event during their lifetimes. However, women are twice as likely as men to experience negative psychiatric outcomes following trauma, including post-traumatic stress disorder (PTSD) and depression. The reason for the increased prevalence in women is unclear, partially because of the historical lack of investigation of females in both human and pre-clinical animal research. The researchers propose to investigate the role of sex hormones in contributing to women's risk for PTSD. The study will investigate relationships between trauma exposure and women's menstrual cycle, examining key events in the cycle, including menstruation, ovulation, and mood changes. The study will then examine relationships between the level of naturally-cycling estradiol (E2; the primary female sex hormone), and brain-based measures of stress vulnerability. This includes amygdala hyper-reactivity to threat.

The trial will study if trauma-exposed women with lower E2 levels during the luteal phase will report greater PTSD symptoms, and show more stress-vulnerable patterns of brain function. It will also examine the effects of exogenous application of estrogen on PTSD symptoms.

Women will begin tracking their cycle using a free and widely-used cycle-tracking smartphone app "Clue" for one full menstrual cycle.

* For Study Aims 1 \& 2 (N=120): Participants will be contacted on the first day of their menstrual period in the second cycle, and scheduled for an MRI with a 4-day window (early follicular phase). Participants will be randomized to begin with either the E2 or placebo patch. The will receive an E2 or placebo patch 1 day prior to the MRI visit, with a blood draw on the morning of the MRI visit (to assess hormone levels), 1 hour prior to scanning. On the first day of the third cycle (onset of menses), women will all be scheduled for their second MRI visit. Participants will experience the opposite condition from their first MRI scan. They will receive an E2 or placebo patch 1 day prior to the MRI visit in the afternoon, with a blood draw on the morning of the MRI visit, 1 hour prior to scanning.
* For Study Aim 3 (N=120): Participants will begin daily urine ovulation tests on Day 11 of their cycle, and will record the results in Clue. When participants record a positive ovulation test during the second month of cycle monitoring, they will be contacted to schedule their MRI visit 5-7 days following ovulation (during the luteal phase). The experimental protocol will otherwise be the same as in Aims 1 and 2, with participants randomized to either E2 or placebo at the first visit and returning the next month for the other condition.

The scientific premise of this study is that low E2 may contribute to stress vulnerability in women. Findings may aid in the development of treatments that will enhance women's mental health outcomes following trauma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PTSD Trauma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Women will participate in one cycle with the estrogen patch and one cycle with the placebo patch. Each cohort will include 40 participants in each of the three study arms for a total of 240 participants.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Randomization will be double blind, with the key held by the study coordinator in a locked file. The study coordinator will do checks of appropriate enrollment to groups after each 20 participants, but no blind will be broken to individuals analyzing study data. Grady pharmacy services will also hold the randomization schedule, as they will dispense the appropriate patch at the appropriate time point.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: PTSD Receiving Estradiol then Placebo

Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

Group Type EXPERIMENTAL

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 1: PTSD Receiving Placebo then Estradiol

Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

Group Type EXPERIMENTAL

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo

Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol

Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 1: Healthy Controls Receiving Estradiol then Placebo

Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 1: Healthy Controls Receiving Placebo then Estradiol

Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: PTSD Receiving Estradiol then Placebo

Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

Group Type EXPERIMENTAL

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: PTSD Receiving Placebo then Estradiol

Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

Group Type EXPERIMENTAL

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: Trauma Control Receiving Estradiol, then Placebo

Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: Trauma Control Receiving Placebo then Estradiol

Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: Healthy Control Receiving Estradiol then Placebo

Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Cohort 2: Healthy Control Receiving Placebo then Estradiol

Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.

Group Type ACTIVE_COMPARATOR

Estradiol patch

Intervention Type DRUG

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Placebo patch

Intervention Type OTHER

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estradiol patch

Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.

Intervention Type DRUG

Placebo patch

Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* African American women
* A menstrual period within the past 60 days
* Able and willing to give informed consent
* Must have a smart phone and willing to install the Clue app

Exclusion Criteria

* Women currently taking any form of hormone-based birth control or other hormonal supplement
* Women who are pregnant or breastfeeding
* Current psychoactive medication use
* Nicotine use or smoking
* Hypercoagulable conditions
* History of embolism
* Current symptoms of psychosis or bipolar disorder
* History of major head injury or neurological disorder
* Weight \>250lbs (a maximum weight to allow for participants to fit comfortably inside the bore of the MRI machine) and typical physical contraindications for MRI such as metal implants

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No